Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to CureVac’s three-month volume weighted average price of approx. $3.53 as of June 11, 2025 (...) Upon closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.